News Press Releases

Acorda Therapeutics Named One of the Best Places to Work for in New York

May 4, 2016

Westchester-based biotechnology leader earns sixth consecutive Top 10 ranking

Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the best companies to work for in New York, based on an independent survey by the Best Companies Group (BCG). This is the sixth consecutive year Acorda was among the top 10 best employers in the state.

Acorda was ranked third within the category of large employers, defined as employing more than 250 people. The rankings are determined by feedback from employees about company culture, benefits and overall job satisfaction.

“This recognition reflects the satisfaction our associates derive from our commitment to developing therapies that make a difference in the lives of people with neurological disorders,” said Ron Cohen, M.D., Acorda’s President and CEO. “Bringing novel medicines to market is challenging. Our success is rooted in the values that we share: open communication, integrity, perseverance and, not least, having fun along the way!”

“As a native New Yorker, it’s satisfying to me personally that Acorda is part of the rapidly growing biotechnology hub in the New York metropolitan area,” Cohen added.

The Best Places to Work survey was conducted by BCG, an independent company that manages Best Places to Work programs on state, regional and national levels. The award is a partnership of the New York State Society for Human Resource Management, the Business Council of New York, BCG and Journal Multimedia Corporation.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, epilepsy, post-stroke walking deficits, migraine, and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA^® (dalfampridine) Extended Release Tablets, 10 mg.

For more information, please visit the Company’s website at: www.acorda.com.

Forward Looking Statements

This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: the ability to complete the Biotie transaction on a timely basis or at all; the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the ability to successfully integrate Biotie’s operations and Civitas’ operations, respectively, into our operations; we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms; our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including CVT-301, Plumiaz (diazepam) Nasal Spray, or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market CVT-301, Plumiaz, any other products under development, or the products that we would acquire if we complete the Biotie transaction; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain and maintain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaborator Biogen in connection therewith; competition; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.